AN2 Other Current Liab vs Other Stockholder Equity Analysis

ANTX Stock

USD 1.99 0.05 2.45%

AN2 Therapeutics financial indicator trend analysis is way more than just evaluating AN2 Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AN2 Therapeutics is a good investment. Please check the relationship between AN2 Therapeutics Other Current Liab and its Other Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AN2 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.

Other Current Liab vs Other Stockholder Equity

Other Current Liab vs Other Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AN2 Therapeutics Other Current Liab account and Other Stockholder Equity. At this time, the significance of the direction appears to have almost identical trend.

The correlation between AN2 Therapeutics' Other Current Liab and Other Stockholder Equity is 0.94. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of AN2 Therapeutics, assuming nothing else is changed. The correlation between historical values of AN2 Therapeutics' Other Current Liab and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of AN2 Therapeutics are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Other Current Liab i.e., AN2 Therapeutics' Other Current Liab and Other Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.94

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Other Current Liab

Other Stockholder Equity

Most indicators from AN2 Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AN2 Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AN2 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.Selling General Administrative is likely to drop to about 7.7 M in 2024. Issuance Of Capital Stock is likely to drop to about 65.6 M in 2024

	2021	2022	2023	2024 (projected)
Interest Income	69K	1.4M	1.6M	1.6M
Net Interest Income	69K	1.4M	1.6M	1.6M

Interest Income Net Interest Income

AN2 Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Other Liab	Other Stockholder Equity	Net Invested Capital	Net Working Capital	Non Currrent Assets Other	Other Assets	Deferred Long Term Liab	Property Plant And Equipment Net	Non Current Liabilities Other	Short Term Debt
Total Assets		-0.79	0.86	0.88	0.75	0.78	-0.88	-0.92	0.93	0.87	0.99	0.81	0.19	0.94	0.33	1.0	-0.96	0.73	0.83	0.99	-0.85	-0.86	-0.56	-0.56	-0.56	-0.56
Short Long Term Debt Total	-0.79		-0.76	-0.77	-0.49	-0.55	0.75	0.8	-0.81	-0.7	-0.8	-0.59	-0.44	-0.82	-0.57	-0.8	0.85	-0.55	-0.64	-0.83	0.69	0.69	0.53	0.53	0.53	0.53
Other Current Liab	0.86	-0.76		1.0	0.88	0.89	-0.72	-0.99	0.97	0.67	0.84	0.94	-0.01	0.75	0.15	0.84	-0.82	0.94	0.94	0.86	-0.84	-0.98	-0.9	-0.9	-0.9	-0.9
Total Current Liabilities	0.88	-0.77	1.0		0.89	0.9	-0.76	-1.0	0.98	0.71	0.86	0.93	0.01	0.78	0.17	0.86	-0.85	0.93	0.94	0.89	-0.86	-0.98	-0.88	-0.88	-0.88	-0.88
Total Stockholder Equity	0.75	-0.49	0.88	0.89		1.0	-0.73	-0.87	0.87	0.7	0.74	0.85	-0.43	0.66	-0.27	0.74	-0.64	0.96	0.98	0.76	-0.91	-0.96	-0.79	-0.79	-0.79	-0.79
Net Tangible Assets	0.78	-0.55	0.89	0.9	1.0		-0.78	-0.89	0.89	0.75	0.78	0.84	-0.38	0.71	-0.22	0.78	-0.68	0.95	0.99	0.8	-0.94	-0.96	-0.77	-0.77	-0.77	-0.77
Net Debt	-0.88	0.75	-0.72	-0.76	-0.73	-0.78		0.8	-0.87	-0.99	-0.92	-0.55	-0.11	-0.97	-0.24	-0.92	0.89	-0.61	-0.8	-0.93	0.94	0.77	0.45	0.45	0.45	0.45
Retained Earnings	-0.92	0.8	-0.99	-1.0	-0.87	-0.89	0.8		-0.99	-0.75	-0.9	-0.92	-0.04	-0.83	-0.21	-0.9	0.88	-0.91	-0.94	-0.92	0.88	0.98	0.84	0.84	0.84	0.84
Accounts Payable	0.93	-0.81	0.97	0.98	0.87	0.89	-0.87	-0.99		0.83	0.93	0.86	0.08	0.89	0.24	0.93	-0.92	0.87	0.93	0.96	-0.92	-0.96	-0.79	-0.79	-0.79	-0.79
Cash	0.87	-0.7	0.67	0.71	0.7	0.75	-0.99	-0.75	0.83		0.91	0.51	0.1	0.96	0.22	0.91	-0.87	0.55	0.76	0.92	-0.92	-0.73	-0.37	-0.37	-0.37	-0.37
Cash And Short Term Investments	0.99	-0.8	0.84	0.86	0.74	0.78	-0.92	-0.9	0.93	0.91		0.76	0.21	0.97	0.35	1.0	-0.97	0.69	0.82	0.99	-0.87	-0.84	-0.53	-0.53	-0.53	-0.53
Common Stock Shares Outstanding	0.81	-0.59	0.94	0.93	0.85	0.84	-0.55	-0.92	0.86	0.51	0.76		-0.14	0.6	0.02	0.76	-0.7	0.94	0.87	0.76	-0.7	-0.93	-0.83	-0.83	-0.83	-0.83
Non Current Liabilities Total	0.19	-0.44	-0.01	0.01	-0.43	-0.38	-0.11	-0.04	0.08	0.1	0.21	-0.14		0.29	0.99	0.21	-0.4	-0.34	-0.28	0.22	0.17	0.17	0.13	0.13	0.13	0.13
Other Current Assets	0.94	-0.82	0.75	0.78	0.66	0.71	-0.97	-0.83	0.89	0.96	0.97	0.6	0.29		0.42	0.97	-0.96	0.57	0.75	0.97	-0.87	-0.76	-0.44	-0.44	-0.44	-0.44
Total Liab	0.33	-0.57	0.15	0.17	-0.27	-0.22	-0.24	-0.21	0.24	0.22	0.35	0.02	0.99	0.42		0.35	-0.54	-0.18	-0.12	0.37	0.02	0.0	-0.02	-0.02	-0.02	-0.02
Total Current Assets	1.0	-0.8	0.84	0.86	0.74	0.78	-0.92	-0.9	0.93	0.91	1.0	0.76	0.21	0.97	0.35		-0.97	0.69	0.82	0.99	-0.87	-0.84	-0.53	-0.53	-0.53	-0.53
Other Liab	-0.96	0.85	-0.82	-0.85	-0.64	-0.68	0.89	0.88	-0.92	-0.87	-0.97	-0.7	-0.4	-0.96	-0.54	-0.97		-0.62	-0.74	-0.98	0.8	0.79	0.56	0.56	0.56	0.56
Other Stockholder Equity	0.73	-0.55	0.94	0.93	0.96	0.95	-0.61	-0.91	0.87	0.55	0.69	0.94	-0.34	0.57	-0.18	0.69	-0.62		0.96	0.72	-0.81	-0.97	-0.9	-0.9	-0.9	-0.9
Net Invested Capital	0.83	-0.64	0.94	0.94	0.98	0.99	-0.8	-0.94	0.93	0.76	0.82	0.87	-0.28	0.75	-0.12	0.82	-0.74	0.96		0.84	-0.94	-0.98	-0.81	-0.81	-0.81	-0.81
Net Working Capital	0.99	-0.83	0.86	0.89	0.76	0.8	-0.93	-0.92	0.96	0.92	0.99	0.76	0.22	0.97	0.37	0.99	-0.98	0.72	0.84		-0.89	-0.87	-0.59	-0.59	-0.59	-0.59
Non Currrent Assets Other	-0.85	0.69	-0.84	-0.86	-0.91	-0.94	0.94	0.88	-0.92	-0.92	-0.87	-0.7	0.17	-0.87	0.02	-0.87	0.8	-0.81	-0.94	-0.89		0.9	0.64	0.64	0.64	0.64
Other Assets	-0.86	0.69	-0.98	-0.98	-0.96	-0.96	0.77	0.98	-0.96	-0.73	-0.84	-0.93	0.17	-0.76	0.0	-0.84	0.79	-0.97	-0.98	-0.87	0.9		0.86	0.86	0.86	0.86
Deferred Long Term Liab	-0.56	0.53	-0.9	-0.88	-0.79	-0.77	0.45	0.84	-0.79	-0.37	-0.53	-0.83	0.13	-0.44	-0.02	-0.53	0.56	-0.9	-0.81	-0.59	0.64	0.86		1.0	1.0	1.0
Property Plant And Equipment Net	-0.56	0.53	-0.9	-0.88	-0.79	-0.77	0.45	0.84	-0.79	-0.37	-0.53	-0.83	0.13	-0.44	-0.02	-0.53	0.56	-0.9	-0.81	-0.59	0.64	0.86	1.0		1.0	1.0
Non Current Liabilities Other	-0.56	0.53	-0.9	-0.88	-0.79	-0.77	0.45	0.84	-0.79	-0.37	-0.53	-0.83	0.13	-0.44	-0.02	-0.53	0.56	-0.9	-0.81	-0.59	0.64	0.86	1.0	1.0		1.0
Short Term Debt	-0.56	0.53	-0.9	-0.88	-0.79	-0.77	0.45	0.84	-0.79	-0.37	-0.53	-0.83	0.13	-0.44	-0.02	-0.53	0.56	-0.9	-0.81	-0.59	0.64	0.86	1.0	1.0	1.0

Click cells to compare fundamentals

AN2 Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether AN2 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AN2 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of An2 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on An2 Therapeutics Stock:

How To Invest In AN2

Details

Is AN2 Stock a good investment?

Details

What is AN2 Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AN2 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.

You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for AN2 Stock analysis

When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories

Is AN2 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AN2 Therapeutics. If investors know AN2 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AN2 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.51)

Return On Assets

(0.36)

Return On Equity

(0.59)

The market value of AN2 Therapeutics is measured differently than its book value, which is the value of AN2 that is recorded on the company's balance sheet. Investors also form their own opinion of AN2 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is AN2 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AN2 Therapeutics' market value can be influenced by many factors that don't directly affect AN2 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AN2 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AN2 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AN2 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AN2 Other Current Liab vs Other Stockholder Equity Analysis

Other Current Liab vs Other Stockholder Equity

Other Current Liab vs Other Stockholder Equity Correlation Analysis

Correlation Coefficient

Other Current Liab

Other Stockholder Equity

AN2 Therapeutics fundamental ratios Correlations

AN2 Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Complementary Tools for AN2 Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Net	+ 1.0	Deferred Long Term Liab
Non Current Liabilities Other	+ 1.0	Deferred Long Term Liab

Retained Earnings	- 1.0	Total Current Liabilities
Accounts Payable	- 0.99	Retained Earnings
Cash	- 0.99	Net Debt
Retained Earnings	- 0.99	Other Current Liab
Other Assets	- 0.98	Net Invested Capital
Net Working Capital	- 0.98	Other Liab